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Molecular Studies of Phenotype Variation in Canine RPGR-XLPRA1
Abstract
Purpose: Canine X-linked progressive retinal atrophy 1 (XLPRA1) caused by a mutation in retinitis
pigmentosa (RP) GTPase regulator (RPGR) exon ORF15 showed significant variability in disease onset in a
colony of dogs that all inherited the same mutant X chromosome. Defective protein trafficking has been
detected in XLPRA1 before any discernible degeneration of the photoreceptors. We hypothesized that the
severity of the photoreceptor degeneration in affected dogs may be associated with defects in genes involved
in ciliary trafficking. To this end, we examined six genes as potential disease modifiers. We also examined the
expression levels of 24 genes involved in ciliary trafficking (seven), visual pathway (five), neuronal
maintenance genes (six), and cellular stress response (six) to evaluate their possible involvement in early
stages of the disease.
Methods: Samples from a pedigree derived from a single XLPRA1-affected male dog outcrossed to unrelated
healthy mix-bred or purebred females were used for immunohistochemistry (IHC), western blot, mutational
and haplotype analysis, and gene expression (GE). Cell-specific markers were used to examine retinal
remodeling in the disease. Single nucleotide polymorphisms (SNPs) spanning the entire RPGR interacting
and protein trafficking genes (RAB8A, RPGRIP1L, CEP290, CC2D2A, DFNB31, and RAB11B) were
genotyped in the pedigree. Quantitative real-time PCR (qRT-PCR) was used to examine the expression of a
total of 24 genes, including the six genes listed.
Results: Examination of cryosections from XLPRA1-affected animals of similar age (3–4 years) with different
disease severity phenotype revealed mislocalization of opsins and upregulation of the Müller cell gliosis
marker GFAP. Four to ten haplotypes per gene were identified in RAB8A, RPGRIP1L, CEP290, CC2D2A,
DFNB31, and RAB11B for further assessment as potential genetic modifiers of XLPRA1. No correlation was
found between the haplotypes and disease severity. During mutational analysis, several new variants,
including a single intronic mutation in RAB8A and three mutations in exon 3 of DFNB31were described
(c.970G>A (V324I), c.978T>C (G326=), and c.985G>A (A329T)). Expression analysis of stress response
genes in 16-week-old predisease XLPRA1 retinas revealed upregulation of GFAP but not HSPA5, DDIT3,
HSPA4, HSP90B1, or HIF1A. Western blot analysis confirmed GFAP upregulation. In the same predisease
group, no significant differences were found in the expression of 18 selected genes (RHO, OPN1LW,
OPN1MW, RLBP1, RPGRORF15, RAB8A, RPGRIP1L, CEP290, CC2D2A, DFNB31, RAB11B, CRX,
RCVRN, PVALB, CALB1, FGFR1, NTRK2, and NTRK3) involved in neuronal function.
Conclusions: Lack of association between haplotypes of RAB8A, RPGRIP1L, CEP290, CC2D2A, DFNB31,
and RAB11B and the disease phenotype suggests that these genes are not genetic modifiers of XLPRA1.
Upregulation of GFAP, an established indicator of the Müller cell gliosis, manifests as an important early
feature of the disease.
Disciplines
Medicine and Health Sciences | Veterinary Medicine
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Retinitis pigmentosa (RP) is the clinical rubric for a 
large, heterogeneous group of inherited retinal disorders char-
acterized by progressive photoreceptor degenerative disease 
leading to vision loss [1]. Of these disorders, X-linked RP 
(XLRP) comprises some of the most severe forms of RP and 
accounts for approximately 10% to 20% of all RP cases [2,3]. 
To date, six disease loci (RP2, RP3, RP6, RP23, RP24, and 
RP34) on the X chromosome have been mapped (RetNet), and 
RP3 accounts for approximately 75% of XLRP cases [4,5]. 
Retinitis pigmentosa GTPase regulator (RPGR) is the disease 
gene of the RP3 locus (RPGR-XLRP) [6,7].
The RPGR gene produces multiple alternatively spliced 
transcripts, all of which encode an N-terminal RCC1-like 
domain that is structurally similar to the RCC1 protein [6], 
a guanine nucleotide exchange factor for the Ran GTPase. 
One major constitutive isoform spans exons 1 through 19 
and carries a C-terminal isoprenylation site. The other major 
variant contains exons 1 to 14 and terminates with a large, 
alternative ORF15 exon (RPGRorf15) [6-9]. The RPGRorf15 
isoform is expressed predominantly in photoreceptor 
connecting cilia and basal bodies [10,11] and appears to be 
play a critical role in retinal function as multiple disease-
causing mutations have been identified in humans, dogs, and 
mice [6,12,13]. Furthermore, gene augmentation therapy with 
RPGRorf15 preserves function and prevents degeneration in 
these diseases [14,15].
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Molecular studies of phenotype variation in canine RPGR-
XLPRA1
Tatyana Appelbaum, Doreen Becker, Evelyn Santana, Gustavo D. Aguirre
Section of Ophthalmology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA
Purpose: Canine X-linked progressive retinal atrophy 1 (XLPRA1) caused by a mutation in retinitis pigmentosa (RP) 
GTPase regulator (RPGR) exon ORF15 showed significant variability in disease onset in a colony of dogs that all inher-
ited the same mutant X chromosome. Defective protein trafficking has been detected in XLPRA1 before any discernible 
degeneration of the photoreceptors. We hypothesized that the severity of the photoreceptor degeneration in affected dogs 
may be associated with defects in genes involved in ciliary trafficking. To this end, we examined six genes as potential 
disease modifiers. We also examined the expression levels of 24 genes involved in ciliary trafficking (seven), visual 
pathway (five), neuronal maintenance genes (six), and cellular stress response (six) to evaluate their possible involvement 
in early stages of the disease.
Methods: Samples from a pedigree derived from a single XLPRA1-affected male dog outcrossed to unrelated healthy 
mix-bred or purebred females were used for immunohistochemistry (IHC), western blot, mutational and haplotype 
analysis, and gene expression (GE). Cell-specific markers were used to examine retinal remodeling in the disease. 
Single nucleotide polymorphisms (SNPs) spanning the entire RPGR interacting and protein trafficking genes (RAB8A, 
RPGRIP1L, CEP290, CC2D2A, DFNB31, and RAB11B) were genotyped in the pedigree. Quantitative real-time PCR 
(qRT-PCR) was used to examine the expression of a total of 24 genes, including the six genes listed.
Results: Examination of cryosections from XLPRA1-affected animals of similar age (3–4 years) with different dis-
ease severity phenotype revealed mislocalization of opsins and upregulation of the Müller cell gliosis marker GFAP. 
Four to ten haplotypes per gene were identified in RAB8A, RPGRIP1L, CEP290, CC2D2A, DFNB31, and RAB11B for 
further assessment as potential genetic modifiers of XLPRA1. No correlation was found between the haplotypes and 
disease severity. During mutational analysis, several new variants, including a single intronic mutation in RAB8A and 
three mutations in exon 3 of DFNB31 were described (c.970G>A (V324I), c.978T>C (G326=), and c.985G>A (A329T)). 
Expression analysis of stress response genes in 16-week-old predisease XLPRA1 retinas revealed upregulation of 
GFAP but not HSPA5, DDIT3, HSPA4, HSP90B1, or HIF1A. Western blot analysis confirmed GFAP upregulation. In the 
same predisease group, no significant differences were found in the expression of 18 selected genes (RHO, OPN1LW, 
OPN1MW, RLBP1, RPGRORF15, RAB8A, RPGRIP1L, CEP290, CC2D2A, DFNB31, RAB11B, CRX, RCVRN, PVALB, 
CALB1, FGFR1, NTRK2, and NTRK3) involved in neuronal function.
Conclusions: Lack of association between haplotypes of RAB8A, RPGRIP1L, CEP290, CC2D2A, DFNB31, and RAB11B 
and the disease phenotype suggests that these genes are not genetic modifiers of XLPRA1. Upregulation of GFAP, an 
established indicator of the Müller cell gliosis, manifests as an important early feature of the disease.
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To date, the X-linked progressive retinal atrophy 
(XLPRA) dog is the only known naturally occurring large 
animal model of RPGR mutations [12]. The canine XLPRA 
phenotype has been linked to RPGR, and homology of canine 
XLPRA and human RP3 has been established [16,17]. Two 
disease-causing microdeletion mutations in exon ORF15 have 
been identified in canine RPGR [12]. One produces a prema-
ture stop (del1028–1032) resulting in a C-terminal truncation 
of 230 residues in XLPRA1. The second is a 2 nt deletion 
(del1084–1085) that causes a frameshift with the inclusion 
of 34 basic amino acids and truncation of the terminal 161 
residues and is causal for XLPRA2. The phenotype associ-
ated with the frameshift mutation in XLPRA2 is severe and 
consistent, and manifests during retinal development; the 
phenotype resulting from XLPRA1 is expressed only after 
normal photoreceptor morphogenesis has been completed and 
has more gradual progression [12].
Extensive phenotypic diversity is observed in patients 
with RPGR mutations, between patients with different 
mutations, and between patients within families who have 
the same mutation [18-20]. Dogs with XLPRA1 also show 
remarkable phenotypic variability in clinical cases and, 
more surprisingly, within a closed research colony where 
all dogs are maintained in a constant environment, exposed 
to the same light intensities and cycles, and fed a uniform 
diet [21,22]. Such phenotypic variability cannot be simply 
explained by heterogeneity at the primary locus since all 
affected dogs inherited the same single mutant X chromo-
some, and the mutation is stably present through multiple 
generations [12,21]. Since genetic modifiers can alter the 
course of diseases, including RPGR-XLRP [18,23-25], we 
hypothesized that a modifier gene or genes contribute to the 
phenotypic variability observed in XLPRA1. Previously, we 
analyzed six genes (RPGRIP1, RANBP2, NPM1, PDE6D, 
NPHP5, and ABCA4) as genetic modifiers of XLPRA1 but 
excluded all [22]. As studies on RPGR-interacting proteins 
and those in the RPGRKO model suggest that RPGR func-
tions in ciliary trafficking [9,26], here we focused on modifier 
genes that might also affect ciliary transport, thus potentiating 
the opsin mislocalization that contributes to XLPRA1 [27]. 
Candidate gene modifiers of XLPRA1 were chosen based on 
their contribution to ciliary formation, vesicular transport, 
and rod outer segment disc formation [28].
In the present study, we characterized retinas from 
XLPRA1 dogs with different degrees of disease for the 
expression of opsins and the Müller cell marker glial fibril-
lary acidic protein (GFAP), which responds to outer retinal 
stress and is one of the earliest genes upregulated in several 
non-allelic forms of inherited retinal degeneration [29,30]. 
We expanded the analysis of genetic modifiers of XLPRA1 
to include genes that encode RPGR-interacting proteins 
(RPGRIP1L [25,31], DFNB31 [32], and RAB8A [33]) and 
proteins essential for cilia formation, ciliary trafficking, and 
cargo delivery (CEP290 [9], RAB11B [34], and CC2D2A 
[35]). We also examined the expression of 24 genes involved 
in ciliary trafficking, visual pathway, neuronal maintenance, 
and cellular stress response to evaluate their possible involve-
ment in early stages of XPLRA1 disease.
METHODS
Ethics statement: The research was conducted in full compli-
ance and strict accordance with the Association for Research 
in Vision and Ophthalmology (ARVO) Resolution on the Use 
of Animals in Ophthalmic and Vision Research. The protocol 
was approved by the University of Pennsylvania Institutional 
Animal Care and Use Committee (IACUC).
Pedigree resources and determination of the phenotypic 
status: Details of the origin and composition of the colony 
have been previously published [21,22,36]. Briefly, the colony 
was established by outcrossing a single XLPRA1-affected 
male Siberian husky to unrelated healthy female beagles 
shown to be free from inherited retinal degeneration based 
on test breeding to known homozygous affected dogs with 
other autosomal recessive diseases [37]. The carrier progeny 
were subsequently mated with mixed breed or purebred dogs 
of varied genetic background to produce informative hemizy-
gous or homozygous affected males or females, respectively, 
and heterozygous females. All dogs were maintained under 
specific and standard conditions where all animals have the 
same exposure to cyclic light (12 h:12 h light-dark cycle), 
receive the same diet, and have the same medical procedures 
and vaccinations. A subset of the colony, consisting of 43 
dogs (affected with the RPGR mutation (n = 24), carriers 
(n = 7), and healthy (n = 12)), was selected for the studies 
(Appendix 1). The dogs in the study were the same used in 
a prior analysis of potential candidate gene disease modi-
fiers [22]. Dogs were included based on the results of serial 
clinical assessment of retinal disease status using indirect 
ophthalmoscopy and electroretinography (ERG). Morpho-
logic criteria were used to establish grades of disease severity 
taking into account the animal’s age and the degree and extent 
of disease [21]. Three grades were defined: Mild degenera-
tion present only in periphery after 1.5 years of age or later, 
Moderate degeneration present only degeneration develops 
between 11 and 15 months of age, and Severe (photoreceptor 
degeneration stage 2 or more advanced, present centrally and 
peripherally) [21]. Of the 24 affected dogs (22 hemizygous 
males and two homozygous females), 14 were classified as 
Molecular Vision 2016; 22:319-331 <http://www.molvis.org/molvis/v22/319> © 2016 Molecular Vision 
321
Severe, nine as Moderate, and one as Mild. The skewed 
phenotype distribution results from selective breeding to 
produce affected dogs that could be diagnosed at an early 
age to be ascertained for the linkage mapping and gene and 
mutation identification studies [12,17]. As the group of dogs 
with Mild disease contained only one dog, in the disease-
association studies only those with Moderate and Severe 
disease were used for analysis.
Sample collection, DNA/RNA extraction, and cDNA 
synthesis: Retinas were collected from enucleated eyes under 
sterile and RNase-free conditions, frozen by immersion in 
liquid nitrogen, and stored at -70 °C until used. For terminal 
procedures, the dogs were anesthetized by intravenous injec-
tion of pentobarbital sodium (65 mg/ml solution was prepared 
under sterile conditions by the Penn Medicine Investigational 
Drug Service), the eyes enucleated, and the dogs immediately 
euthanatized with intravenous Euthasol (Virbac, Ft. Worth, 
TX). Total RNA was isolated from canine tissues using a 
modified TRIzol and single chloroform extraction protocol. 
Briefly, 1 ml of TRIzol (Invitrogen, Carlsbad, CA) was added 
to the retina, and 0.2 ml of chloroform (Sigma-Aldrich, Allen-
town, PA) was added after tissue homogenization; the tissue-
Trizol-chloroform mix then was centrifuged at 1,484 ×g at 4 
°C for 4 min. The clear aqueous upper phase was transferred 
to a fresh microfuge tube and mixed to 70% ethanol (1:1, 
V/V). Next, the sample was loaded on an RNeasy Mini spin 
column, and the RNA was further purified using an RNeasy 
kit (Qiagen, Valencia, CA) following the manufacturer’s 
directions. First-strand cDNA was synthesized in 20 μl reac-
tions using the High Capacity RNA-to-cDNA kit (Applied 
Biosystems, Foster City, CA) following the manufacturer’s 
recommendations. Genomic DNA was isolated from blood 
samples using the QIAamp DNA kit (Qiagen) following the 
manufacturer’s directions.
Genotype and haplotype analysis within candidate genes: 
Six genes were chosen for analysis (RAB8A, RPGRIP1L, 
CEP290, CC2D2A, DFNB31, and RAB11B). Polymorphic 
sites consisting of SNPs were identified in selected genes 
based on the Broad Institute SNP database, the Dog Genome 
SNP Database, and SNP database or based on our own gene 
sequencing analyses. Genotyping was performed using direct 
sequencing of PCR products. PHASE software (v. 2.1.1) was 
used for haplotype reconstruction. Fisher’s exact test (two-
sided) was used for statistical analysis (p≤0.05). For this 
analysis, we posited that a candidate gene modifier would 
have a homozygous haplotype in dogs with Severe phenotype 
and heterozygous in those with a Moderate phenotype.
PCR amplification and sequencing: Primer sequences for the 
PCR experiments are shown in Appendix 2. PCR reactions 
were performed on 50 ng genomic DNA in a final volume 
of 25 μl containing 2x PCR master Mix (New England 
Biolabs, Ipswich, MA), 0.7 μM forward and reverse primers, 
and PCR-grade water. Cycling conditions were 2 min initial 
denaturation at 95 °C followed by 35 cycles of 95 °C for 20 
s (denaturation), 52 °C for 30 s (annealing), and 68 °C for 
30 s (elongation). For sequencing purposes, the PCR prod-
ucts were analyzed on a 2% agarose gel, extracted with the 
NucleoTrap Gel Extraction Kit (Clontech, Mountain View, 
CA), and directly sequenced.
Relative quantification (ddCt) assay: Real-time PCR was 
performed in a total volume of 20 μl in 96-well microwell 
plates on the Applied Biosystems 7500 Real-Time PCR 
System. All PCRs were performed using cDNA generated 
from 15 ng DNase-treated RNA from 16-week-old healthy 
retinas (n = 3) and XLPRA1-affected dogs (n = 6). The SYBR 
Green platform was used for gene expression analysis of 24 
genes using a primer concentration of 0.2 μM. The primer 
sequences for real-time PCR are listed in Appendix 3. 
The TBP gene expression level was used to normalize the 
cDNA templates. Amplification data were analyzed with the 
7500 Software version 2.0.1 (Applied Biosystems). Genes 
included for this analysis coded for proteins essential for 
cilia formation, ciliary trafficking, and cargo delivery, and 
genes involved in ciliary formation, visual pathway, neuronal 
maintenance, and cellular stress response; the genes are listed 
in Table 1.
Fluorescent immunohistochemistry: Retina from three 
XLPRA1-affected dogs and a healthy dog was used for 
immunohistochemistry (IHC). These dogs are not part of the 
genetic modifier pedigree. The procedures used for tissue 
collection, preparation, and sectioning have been previously 
described [38]. Cryosections were washed and treated with 
the primary antibodies in PBS solution (1X; 137 mM NaCl, 
2.7 mM KCl, 8 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.4), 3% 
normal horse serum (NHS, Vector Laboratories, Burlingame, 
CA), 1% bovine serum albumin (BSA, Sigma-Aldrich) and 
0.3% Triton X-100 (Sigma-Aldrich) overnight followed by 
incubation with appropriate fluorescent secondary antibodies 
(Alexa Fluor Dyes, 1:300; Molecular Probes, Eugene, OR). 
The following primary antibodies were used in the study: 
mouse anti-rhodopsin at 1:1,000 (MAB5316, Chemicon, 
Temecula, CA), rabbit anti-L/M opsin at 1:1,000 (AB5405, 
Millipore, Billerica, MA), goat anti-hCAR (human cone 
arrestin) at 1:1,000 (a gift from Dr. W. Beltran, University 
of Pennsylvania), and rabbit anti-GFAP at 1:1,000 (Z0334, 
Dako, Carpinteria, CA). 4’, 6-diamidino-2-phenylindole 
(DAPI, Sigma-Aldrich) stain was used to label the cell nuclei. 
Slides were mounted with fluoromount G mounting media 
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(catalog No. 01100-01; Southern Biotech, Birmingham, AL), 
coverslipped, and examined with epifluorescence microscopy 
with a Zeiss Axioplan microscope (Carl Zeiss Meditech, 
Oberkochen, Germany). Images were digitally captured (Spot 
4.0 camera; Diagnostic Instruments, Inc., Sterling Heights, 
MI) and imported into a graphics program (Photoshop; 
Adobe, Mountain View, CA) for display.
Western blot analysis: Western blotting was performed with 
multiplex infrared detection using secondary antibodies 
conjugated to IRDye® fluorescent dyes. Briefly, total protein 
extracts in equal amounts (50 µg) as determined with the 
BCA Protein Assay Kit (Thermo Fisher Scientific, Rock-
ford, IL) were resolved using 4–15% acrylamide gradient 
sodium dodecyl sulfate–polyacrylamide gel electrophoresis 
(SDS–PAGE gel; Bio-Rad Laboratories, Hercules, CA) in 
Tris/glycine/SDS buffer (BioRad). Resolved proteins were 
immunoblotted into nitrocellulose membranes (LI-COR 
Biosciences, Lincoln, NE) using the Wet/Tank Blotting 
System (Bio-Rad) and blocked for 1 h at room tempera-
ture or overnight at 4 °C with 1× Odyssey Blocking Buffer 
(LI-COR). Immunoblots were probed overnight at 4 °C with 
unconjugated primary antibodies diluted in 1× Blocking 
Buffer. Membranes were then washed 3X with PBST (PBS 
containing 0.1% Tween 20 (Sigma-Aldrich) and incubated for 
1 h at room temperature in goat anti-rabbit IRDye680RD- and 
goat anti-mouse IRDye800CW-conjugated immunoglobulin 
G (IgG) secondary antibodies (LI-COR) diluted 1/10,000 
each in 1× Blocking Buffer containing 0.1% Tween-20. 
Immunoblots were washed three times in PBST, once in PBS, 
and scanned on the Li-COR Odyssey Fc Dual-Mode Imaging 
System with 700- and 800-nm channels. Normalization to 
ACTB and analyses were done using Image Studio Software 
provided by LI-COR. The primary antibodies used were 
rabbit anti-GFAP at 1:5,000 (Z0334, Dako) and anti-mouse 
ACTB at 1:10,000 (MAB1501, Millipore). Quantification of 
the proteins on western blot was performed with Li-COR 
Odyssey software.
Table 1. RNa expRessioN chaNges of ReTiNal geNes iN 16 week old xlpRa1 ReTiNas.
Gene Gene name FC* XLPRA1 versus normal retina
RHO rhodopsin    n.s.**
OPN1LW opsin 1 (cone pigments), long-wave-sensitive n.s.
OPN1MW opsin 1 (cone pigments), medium-wave-sensitive n.s.
RLBP1 retinaldehyde binding protein 1 n.s.
RPGRORF15 retinitis pigmentosa GTPase regulator n.s.
RAB8A RAB8A, member RAS oncogene family n.s.
RPGRIP1L RPGRIP1-like n.s.
CEP290 centrosomal protein 290 kDa n.s.
CC2D2A coiled-coil and C2 domain containing 2A n.s.
DFNB31 deafness, autosomal recessive 31 n.s.
RAB11B RAB11B, member RAS oncogene family n.s.
CRX cone-rod homeobox n.s.
RCVRN recoverin n.s.
PVALB parvalbumin n.s.
CALB1 calbindin 1 n.s.
FGFR1 fibroblast growth factor receptor 1 n.s.
NTRK2 neurotrophic tyrosine kinase, receptor, type 2 n.s.
 NTRK3 neurotrophic tyrosine kinase, receptor, type 3 n.s.
GFAP glial fibrillary acidic protein 6.7
HSPA5 heat shock 70 kDa protein 5 n.s.
DDIT3 DNA-damage-inducible transcript 3 n.s.
 HSPA4 heat shock 70 kDa protein 4 n.s.
HSP90B1 heat shock protein 90 kDa beta n.s.
HIF1A hypoxia inducible factor 1, alpha subunit n.s.
*FC=fold change differences ** n.s.=non statistically significant differences
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RESULTS
Characterization of XLPRA1-affected dogs with different 
severity phenotype: Examination of hematoxylin and eosin 
(H&E)-stained cryosections from XLPRA1-affected dogs of 
comparable ages (3–4 years) showed morphological altera-
tions compatible with an ongoing disease process (Figure 
1A–D). Disease was accompanied by decreased rod density 
and outer nuclear layer (ONL) thickness. Significant photo-
receptor loss (ONL = 1 row) was observed in the youngest 
animal with Severe phenotype. To evaluate the localization of 
photoreceptor-specific proteins, double immunolabeling and 
DAPI nuclear staining were performed in the affected dogs. 
Immunolabeling with rod opsin showed mislocalization in 
Mild disease and loss of rods in Moderate and Severe disease. 
GFAP was upregulated in all disease phenotypes and was 
mostly present in the inner plexiform layer (IPL) and to a 
lesser extent in the outer plexiform layer (OPL; Figure 1E–H); 
increased GFAP expression was more prominent in Moderate 
and Severe disease. Double immunolabeling with hCAR and 
M/L opsin antibodies showed cone outer segment disorgani-
zation and mislocalization of M/L cone opsin (Figure 1I–L), 
and disorganization and loss of the outer segments (OS) were 
observed in the remaining rods and cones.
Genotype-phenotype analysis in XLPRA1 pedigree: As 
demonstrated previously [27] and in the present study (Figure 
1), XLPRA1 is characterized by defective protein trafficking 
that leads to mislocalization of opsins to the inner segment, 
nuclear, and synaptic layers. Thus, the presence of mutations 
that perturb protein trafficking could have severe functional 
consequences that could result in photoreceptor cell death. To 
this end, six genes (RAB8A, RPGRIP1L, CEP290, CC2D2A, 
DFNB31, and RAB11B) were investigated as candidate disease 
modifiers. The proteins encoded by these genes are involved 
in common and distinct pathways required for effective 
protein trafficking in cilia and cargo delivery, and some 
Figure 1. XLPRA1-affected retina: immunohistochemical characterization of different severity phenotypes. A–D: Hematoxylin and eosin 
(H&E)–stained retinal cryosections from the superior quadrant (6,000 μm from the ora serrata; area is approximately the midpoint between 
the disc and the ora serrata) in dogs of comparable ages that have different phenotype severity. E–H: Double immunolabeling with RHO and 
GFAP antibodies. I–L: Double immunolabeling with hCAR and M/L opsin antibodies. Where appropriate (E, F, I, J), the immunolabeling 
images show the individual blue, green, and red channels with the merged image on the right of each set to show the mislocalization of opsin 
(*). RPE= retinal pigment epithelium; PR = photoreceptors; ONL = outer nuclear layer; OPL = outer plexiform layer; INL = inner nuclear 
layer; IPL = inner plexiform layer; GCL= ganglion cells layer.
Molecular Vision 2016; 22:319-331 <http://www.molvis.org/molvis/v22/319> © 2016 Molecular Vision 
324
(RPGRIP1L, DFNB31, and RAB8A) directly interact with 
RPGR.
Profiling sequence changes in RAB8A, RPGRIP1L, CEP290, 
CC2D2A, DFNB31, and RAB11B genes: Polymorphic markers 
were identified by sequence analysis of randomly selected 
regions within the genes of interest in the XLPRA1-affected 
study dogs. In addition, details of SNPs from several public 
SNP databases used for genotype and haplotype analysis are 
presented in Appendix 2. As two mutations in RPGRIP1L 
(A229T and R744Q) have been previously shown to contribute 
to phenotypic variability in retinal degeneration [18,25], we 
first analyzed the affected RPGR mutant dogs for the pres-
ence of A229T and R744Q. Human and canine RPGRIP1L is 
predicted to have 90.0% amino acid sequencing homology 
(compare NM_015272 and XP_013964947); therefore, A229 
and R744 are in the same position in the human and canine 
RPGRIP1L sequence. None of the dogs analyzed harbored 
either mutation.
Sequence analysis of other genes identified four new 
variants: a single intronic change in RAB8A and three in 
exon 3 of DFNB31 in affected dogs. Sequence changes in 
DFNB31 exon 3 include two missense [(c.970G>A (p.V324I) 
and (c.985G>A (p.A329T))] and one synonymous (c.978T>C 
(p.G326=)) change (Figure 2). We performed alignment of the 
DFNB31 orthologous sequences to see whether the missense 
mutations affected conservative amino acid residues (Figure 
3). Analysis of the corresponding protein region in multiple 
species has identified valine and isoleucine in position 324 of 
DFNB31; thus, it is unlikely that the V324I missense change 
observed in canine DFNB31 is consequential. However, the 
canine sequence has alanine at position 329 of DFNB31 while 
all other analyzed orthologous sequences contain proline. 
Although alanine and proline are hydrophobic neutral amino 
acids, the A329T change found in DFNB31 replaces alanine 
with threonine, a polar and hydrophilic residue that could 
potentially affect the structure and function of the protein. 
However, A329T was not included in the genotype and haplo-
type analysis as A329T was present only in the founder (H2) 
that was a carrier for the mutation.
The DFNB31 variants (V324I and G326=) were 
frequently present in the XLPRA1-affected dogs of the 
pedigree, but neither was associated with disease phenotype 
(Appendix 4). Despite a high prevalence of V324I (69.6% of 
XLPRA1-affected dogs), this variant appeared to have been 
artificially accumulated in the pedigree as the founder (H2), 
and most females used for breeding harbored V324I and 
passed it on to their offspring. Therefore, we concluded that 
the V324I sequence change is unlikely to have any functional 
consequences.
Genotype distribution: Genotype frequencies for the SNPs 
abundant in the XLPRA1-affected dogs are shown in 
Appendix 4 and were compared for the Moderate and Severe 
phenotypes. The genotype distributions of all analyzed SNPs 
were not statistically different between these two groups.
Haplotype distribution: The polymorphic SNPs in Appendix 
2 provide the basis for gene-specific haplotype association 
studies. These results are presented in Table 2 and Table 
3. The number of haplotypes per gene varied from four 
(CEP290) to ten (DFNB31; Table 2). Next, we compared 
the frequencies of haplotypes in the Moderate and Severe 
phenotypes of XLPRA1-affected dogs (Table 3). The haplo-
type frequencies for the genes RAB8A, RPGRIP1L, CEP290, 
CC2D2A, DFNB31, and RAB11B were not statistically 
different between the two groups analyzed in this study, thus 
excluding all six genes as candidate modifiers of the disease 
phenotype observed in the XLPRA1 pedigree.
Gene expression of selected genes in the study model: Varia-
tions in gene expression can also be associated with disease 
[39,40], and the lack of gene expression data for components 
of the RPGR molecular network hinders our understanding 
of its role in phenotypic expression of XLPRA1. In this 
study, we examined the expression of RPGRORF15, RAB8A, 
RPGRIP1L, CEP290, CC2D2A, DFNB31, and RAB11B in six 
XLPRA1-affected predisease (16 week old) retinas to deter-
mine whether expression changes in gene expression might 
contribute to disease progression. To gain more in-depth 
understanding of the disease-induced changes in gene expres-
sion, we also examined the expression of selected genes 
involved in the visual pathway (RHO, OPN1LW, OPN1MW, 
and RLBP1), neuronal cells (CRX, RCVRN, PVALB, CALB1, 
FGFR1, NTRK2, and NTRK3), and cellular stress response 
(GFAP, HSPA5, DDIT3, HSPA4, HSP90B1, and HIF1).
Out of the total 24 genes examined, only GFAP gene 
expression was upregulated (6.7-fold increase) in all XLPRA1 
animals compared to the control group (p<0.01, Table 1). The 
GFAP level in XLPRA1 in the predisease samples was highly 
variable and increased in expression early in other retinal 
degeneration disorders in dogs [29,30]. The estimated vari-
ance in the XLPRA1 group was 9.96 compared to variance 
of only 0.07 in the control group. Upregulation of the GFAP 
protein in the 16-week-old XLPRA1 retinas was confirmed 
with western blot analysis (Figure 4).
DISCUSSION
RPGR is an important component of the ciliary protein 
network, but details of the molecular function of RPGR 
in photoreceptors cilia are still incomplete. The protein 
complexes in which RPGR participates in the ciliary 
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compartment play key roles in the function and maintenance 
of photoreceptor cells. For example, RPGR is associated 
through NPHP1, NPHP5, RPGRIP1, RPGRIP1L, RAB8A, 
CEP290, and SMC1/3 with the nephrocystin protein network 
and ciliary transport [9,41-44], through DFNB31 to the Usher 
protein network [32], and through NPM1 to the centrosomal 
protein network [45]. Defects of proteins in these complexes 
lead to photoreceptor dysfunction, cell death, and retinal 
degeneration.
The mislocalization of opsin is thought to contribute 
to the pathophysiology of photoreceptor degeneration. 
Changes in opsin localization have been reported for many 
diseases and injuries where photoreceptor cell death occurs, 
including human and animal models of retinal degeneration 
[13,27,46,47]. Opsin mislocalization is a feature of XLPRA1 
and XLPRA2 and other canine retinal degeneration disorders 
(Figure 1 and [27,30,48]). Similar to several other RPGR 
disease models [13,49], opsin mislocalization was detected in 
XLPRA1 before any discernible photoreceptor degeneration. 
Since mutations in ciliary trafficking genes can contribute 
to ciliary transport defects, six genes (RAB8A, RPGRIP1L, 
CEP290, CC2D2A, DFNB31, and RAB11B) were selected 
based on their interaction with RPGR or involvement in 
ciliary transport and investigated as candidate genetic modi-
fiers of XLPRA1.
The XLPRA1 pedigree is small, and its inbred affected 
population is not ideal for linkage disequilibrium (LD) 
analysis. Because of these limitations, we compared gene-
specific genotypes and haplotypes frequencies in Severe 
versus Moderate affected dogs to determine whether there 
Figure 2. Chromatograms showing 
the variants detected in the canine 
DFNB31 gene (exon 3). c.970G>A 
and c.985G>A result in a substitu-
tion of valine for isoleucine at 
position 324 and alanine for threo-
nine at position 329 of DFNB31, 
respectively (top). c.978T>C does 
not result in a change in the amino 
acid sequence (bottom). In both 
chromatograms, the relevant area 
is marked with an arrow.
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was a putative correlation between genotype or haplotype and 
disease phenotype. By carrying out this strategy, we found 
that moderately and severely affected dogs had no differ-
ences in genotypes and haplotype frequencies for RAB8A, 
RPGRIP1L, CEP290, CC2D2A, DFNB31, and RAB11B. 
Furthermore, these six genes were not variably expressed in 
predisease XLPRA1 retinas suggesting that the gene products 
do not serve as modifiers of disease phenotype.
During mutational analysis, three novel sequence 
variants were discovered in DFNB31 (V324I, G326, and 
A329T). All three were located in exon 3, which encodes 
part of the PDZ2 domain responsible for binding to the 
C-terminal of RPGRorf15 [32]. V324I was present in 69.6% of 
Figure 3. Multiple alignment of the 
DFNB31 orthologous sequences. 
The alignment shows that verte-
brate DFNB31 orthologs have either 
valine or isoleucine (marked by a 
single asterisk) in the protein region 
corresponding to position 324 of 
the canine DFNB31 and proline or 
alanine (marked by double aster-
isks) at position 329.
Table 2. haploTypes RecoNsTRucTed iN The xlpRa1 pedigRee.
Gene Haplotype Gene Haplotype
RAB8A 1 2 3 4 5 6 7 CC2D2A 1 2 3 4 5 6 7    
chr20:46336246 C C C C C C A chr3:64841219 A A A A T T T    
   46344912 C C C C G G G 64854752 C G T T C C  C    
  46349143 T T C C T C T 64859223 G T C T G T T    
  46351756 G A G A G G G 64861317 A A A A G A G    
RPGRIP1L 1 2 3 4 5 6  DFNB31 1 2 3 4 5 6 7 8 9 10
chr2:62092489 C C C G G G  chr11:68620384 A A A A A G G G G G
62122046 A A A T T T    68642086 T T T G G T T T T T
62138129 A A C A A A    68658508 A A A A A G G G G G
62152007 G G G G A A    68671284 T T C T T T T C C C
62163783 C T T T C T    68671292 G A G A A G G G G G
62166939 C C C T T T    68680635 A G A G G G A G G A
          68698265 C C C C G G C C G C
CEP290 1 2 3 4    RAB11B 1 2 3 4 5 6 7    
chr15:29199693 G G G C    chr20:52957965 C C C C G C A    
  29220545 G G A A       52960719 C C C C C G G    
  29228039 T T C C       52963299 T T C C T C T    
  29247843 A G A A       52965822 G A G A G G G    
  29265700 T T C C               
  29279083 G G A A               
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XLPRA1-affected dogs, suggesting at first that it could be 
associated with disease. However, on closer examination we 
found that this mutation artificially accumulated in the 
Table 3. haploTypes disTRibuTioN iN xlpRa1 affecTed dogs wiTh diffeReNT seveRiTy pheNoType.
Sample ID
RAB8A RPGRIP1L CEP290 CC2D2A DFNB31 RAB11B
Severe
H2 1,2 1,2 1,1 1,2 1,4 1,2
H64 3,4 2,2 2,4 2,3 4,10 3,4
H104 3,5 3,6 2,2 2,3 6,6 3,5
H105 5,5 2,2 2,2 3,7 2,6 5,5
H78 5,5 2,5 2,3 7,7 4,10 5,5
H79 1,5 2,5 2,3 7,7 2,9 1,5
H82 1,5 2,5 1,2 2,7 2,9 1,5
H143 5,7 4,5 1,2 2,6 6,10 5,7
H35 3,5 2,5 3,4 2,2 3,3 3,5
H38 3,7 2,5 1,4 2,2 6,7 1,6
H71 2,3 3,5 1,4 1,1 4,10 2,3
H72 6,7 2,5 1,2 2,7 4,10 6,7
H73 2,5 3,5 1,2 1,1 5,10 2,5
H118 3,7 5,5 2,4 2,2 6,10 3,7
Moderate
H29 5,5 3,6 2.3 3,7 4,9 5,5
H31 5,5 3,5 1,3 1,5 4,10 5,5
H130 3,3 2,5 1,2 2,2 2,6 3,3
H131 3,3 2,5 2,4 4,4 4,6 3,3
H81 5,5 3,3 1,3 5,5 4,4 5,5
H208 2,5 2,4 2,2 2,7 2,6 2,5
H59 4,7 2,5 2,3 2,3 9,10 4,7
H201 2,5 5,5 1,1 2,3 8,10 2,5
H202 3,7 5,5 1,2 3,3 2,9 3,7
Figure 4. Representative western 
blot analysis for GFAP on two 
XLPRA1-affected retinas (S1 
and S2, 16 weeks) versus the 
age-matched healthy retina (16 
weeks). Quantification of proteins 
on western blot performed with 
Li-COR Odyssey software showed 
upregulation of GFAP in S1 and 
S2 retinas of 2.3 and 2.5 times, 
respectively.
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pedigree. Additional analysis of DFNB31 orthologous 
sequences excluded a putative harmful effect of V324I.
In addition to the seven genes involved in protein 
trafficking (RPGRORF15, RAB8A, RPGRIP1L, CEP290, 
CC2D2A, DFNB31, and RAB11B), we analyzed the expres-
sion of a subset of genes necessary for the visual pathway 
(RHO, OPN1LW, OPN1MW, and RLBP1), neuronal cell main-
tenance (CRX, RCVRN, PVALB, CALB1, FGFR1, NTRK2, 
and NTRK3), molecular chaperons (HSPA4, HSP90B1), 
unfolded protein response (HSPA5, DDIT3), cellular 
response to hypoxia (HIF1), and Müller cell gliosis (GFAP) 
in early XLPRA1. Although opsins are mislocalized in early 
XLPRA1 [27], we found that their gene expression was not 
impaired in 16-week-old predegenerate retinas. Aside from 
GFAP, other genes were not differentially expressed. Notably, 
GFAP expression was already upregulated at 16 weeks of age, 
when the XLPRA1 retinas are morphologically normal [21]. 
GFAP expression in Müller cells in the mammalian retina is 
normally low but is upregulated in a variety of degenerative 
conditions, including retinal trauma, diabetic retinopathy 
[50], choroidal neovascularization [51], retinal detachment 
[52], glaucoma [53], and age-related macular degeneration 
[54].
The results obtained in this study clearly demonstrate that 
even when mutated retinas appear morphologically normal, 
the Müller cells respond with a dramatic increase in GFAP 
expression in the early phase of XLPRA1. We also identi-
fied GFAP as highly variable in expression across predisease 
XLPRA1 retinas. Could GFAP gene expression variability 
lead to or be a marker of phenotypic diversity of XLPRA1? It 
is possible. Recent publications describe a complex interplay 
between Müller cells and retinal microglia in pathological 
conditions [55,56] that mediate adaptive responses within the 
retina and may be relevant to amplifying and coordinating 
an inflammatory response. The severity of the photoreceptor 
degeneration in XLPRA1-affected dogs may be associated 
with increased retinal inflammation. Therefore, an inflam-
matory response in the XLPRA1 retina should be further 
investigated.
GFAP typically increases with disease progression but 
decreases in some models in advanced stages of degen-
eration [27,57]. When assessing retinal remodeling events in 
XLPRA1-affected dogs with different severity phenotype, we 
observed markedly higher levels of GFAP in all disease stages 
in comparison to the healthy retina (Figure 1E–H). In addi-
tion, GFAP immunolabeling showed Müller glia reactivity 
increased with severity of the disease. This increase could 
be a sign of a sustained disturbance in retinal homeostasis 
in the disease.
In conclusion, this study reports a lack of associa-
tion between the RAB8A, RPGRIP1L, CEP290, CC2D2A, 
DFNB31, and RAB11B genes and disease severity phenotype 
in canine XLPRA1. Selected genes responsible for neuronal 
cell maintenance and cellular stress response were not differ-
entially expressed in predisease retinas except GFAP, which 
appears to be as an important early feature of the disease.
Current perspectives on the genetic analysis of canine 
XLPRA1: The search for potential genetic modifier(s) of the 
XLPRA1 phenotype will continue. As the next step, we will 
conduct a genome-wide scan in the XLPRA1-affected pedi-
gree to search for loci associated with the disease phenotype.
APPENDIX 1. XLPRA1 PEDIGREE.
To access the data, click or select the words “Appendix 1.” 
H2 is a Siberian husky founder that was outcrossed to dogs 
from various breeds. The following abbreviations were used: 
(B) beagle, (N) mixed breed control, and (E) Norwegian 
elkhound-derived outcross. Severely affected dogs are in 
black, moderately affected dogs in dark gray, and mildly 
affected dogs in crosshatch pattern. Squares represent male 
and circles represent female. Dotted circles are carrier females 
that were not included in the phenotype analysis. (Figure was 
modified from our previously published article [22]).
APPENDIX 2. CHARACTERISTICS OF THE SNP 
MARKER PANEL AND ASSOCIATED PCR PRIMERS 
SEQUENCES
To access the data, click or select the words “Appendix 2.” 
Note: *SNP positions are given according to UCSC Genome 
Browser on Dog May 2011 (Broad/canFam3) assembly; ** 
Mutation position in the protein
APPENDIX 3. REAL-TIME PCR PRIMERS USED IN 
THE STUDY.
To access the data, click or select the words “Appendix 3.”
APPENDIX 4. GENOTYPE FREQUENCIES IN 
XLPRA1 AFFECTED DOGS WITH DIFFERENT 
SEVERITY PHENOTYPES.
To access the data, click or select the words “Appendix 4.”
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